Anadys Pharmaceuticals, Inc. has suspended dosing of ANA 975 in patients with hepatitis C virus infection in its ongoing phase Ib clinical trial

Source: Reactions Weekly, Volume 1, Number 1109, 2006-07-08 , pp. 3-3(1)

Publisher: Adis International

Keywords: ANA-975, adverse reactions; ANA-975, pharmacodynamics; Development-status; Hepatitis-C; Novartis; Research-and-development; Various-toxicities, drug-induced

Document Type: Short communication

Publication date: 2006-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers